US FDA approves Cytokinetics' heart disease drug
Dec 19 (Reuters) - The U.S. Food and Drug Administration has approved Cytokinetics' CYTK.O drug to treat a rare heart condition, the company said on Friday. (Reporting by Kamal Choudhury and Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech